3 New Strong Buy Ratings from Top-Rated Analysts: 05/09/2025

Happy Friday! As our gift to you, here’s a no-cost peek at the latest picks from our Strong Buy Stocks from Top Wall Street Analysts screener:

• Why SAP SE (SAP) is enjoying great sentiment right now
• AbbVie (ABBV) is on a tear following excellent earnings 
• Gold’s bull run continues — and Kinross Gold (KGC) could continue to benefit

P.S. Get more alerts like this daily … Try WallStreetZen Premium.

1. SAP SE (NYSE: SAP)

One of the world’s most successful enterprise software companies, SAP SE helps other companies manage everything from finances, human resources, and supply chains to customer relationships. Its flagship product, SAP S/4HANA, is a cloud-based platform that has attained immense popularity in a wide variety of sectors on account of its ability to both centralize and streamline operations.

Zen Rating: B (Buy) — see full analysis >  

Recent Price: $301.72 — get current quote > 

Max 1-year forecast: $330.00 

Why we’re watching:

• SAP stock currently has 5 analyst ratings — all of which are positive. To be precise, the stock currently has 2 Strong Buy ratings and 1 Buy rating, with no Hold, Sell, or Strong Sell ratings. See the ratings
• Raimo Lenschow of Barclays (a top 2% rated analyst) recently maintained a Strong Buy rating on SAP SE shares, and hiked his price target from $286 to $308.
• Looking ahead from a "strong" Print, Lenschow said management guided conservatively, "providing a buffer for the worsening macro." 
• Unless the macro deteriorates significantly, SAP's FY 2025 year targets are achievable, the analyst continued. "Near-term resilience, combined with a solid structural growth outlook, makes SAP stand out," Lenschow said.
• With that said, Lenschow’s forecast implies a relatively modest upside compared to current prices — but as the stock has an overall Zen Rating of B, it is expected to outperform the wider market. In addition, as there has been an 8.55% price surge in the last week, there’s a good chance that a correction could soon provide a more attractive entry point.
• SAP shares rank in the top 8% in terms of Sentiment. A key contributing factor is the fact that there has been no insider selling of the stock in the past 12 months.
• Moreover, SAP stock ranks in the top 11% when it comes to Momentum.
• However, the star of the show is the stock’s Artificial Intelligence rating — in this category, SAP ranks in the 98th percentile of stocks. (See all 7 Zen Component Grades here >)

2. Kinross Gold (NYSE: KGC) 

Gold is currently in an incredibly strong bull run — and beyond its traditional role as a store of value and a hedge against inflation, it has also become quite the appealing speculative investment. Gold miners provide a more convenient (and usually more profitable) way for investors to benefit — and our Zen Investor Editor-in-Chief has selected Kinross Gold as the pick of the litter.

Zen Rating: A (Strong Buy) — see full analysis >  

Recent Price: $15.10 — get current quote > 

Max 1-year forecast: $16.00 

Why we’re watching:

• Kinross Gold is our Stock of the Week. Steve Reitmeister, our Editor-in-Chief, detailed his rationale in a Tuesday article.
• We strongly suggest have a look at the article itself — but we’ll also summarize some key points here
• For one, KGC is the best-performing stock in Steve’s 16-stock strong Zen Investor portfolio on a year-to-date (YTD) basis, having secured a gain of 52% thus far.
• Present macroeconomic conditions and trade disputes (read tariffs) provide a bevy of tailwinds for gold — and gold miners tend to outperform the commodity itself.
• At present, Kinross Gold is the 3rd highest-rated stock in its industry.
• KGC shares carry an overall Zen Rating of A, and rank in the top 3% of equities based on a holistic analysis of 115 factors that correlate with outsized returns.
• In terms of Component Grade ratings, KGC ranks highly in terms of Financials, Momentum, and Value — in the top 3%, 13%, and 18%, respectively. (See all 7 Zen Component Grades here >)

3. AbbVie (NYSE: ABBV)

AbbVie is a pharmaceutical company that maintains a very diverse set of treatments for chronic conditions, and boasts a promising immunology and oncology pipeline. ABBV stock has been on quite the tear since mid-April, and a recent earnings beat has put it within striking distance of pre-tariff levels. Moreover, it boasts solid growth prospects, as well as a pretty healthy balance sheet.

Zen Rating: A (Strong Buy) — see full analysis >  

Recent Price: $198.47 — get current quote > 

Max 1-year forecast: $250.00  

Why we’re watching:

• A consensus Strong Buy according to Wall Street analysts, ABBV stock currently has 8 Strong Buy ratings, 5 Buy ratings, and 3 Hold ratings. See the ratings  
• Guggenheim researcher Vamil Divan (a top 4% rated analyst) recently maintained a Strong Buy rating on AbbVie stock, and hiked his price target from $214 to $216.
• The analyst cited the double beat the company delivered in its Q1 2025 report as the key catalyst behind his decision. In Q1, earnings per share (EPS) came in at $2.46, outpacing estimates of $2.39, while revenues of $13.34 billion demonstrated strong growth of 8.4% on a year-over-year (YoY) basis
• ABBV is the 5th highest-rated stock in the General Drug Manufacturer industry, which carries an overall rating of A itself.
• AbbVie stock has a Zen Rating of A, and ranks in the top 5% of equities based on 115 proprietary factors that correlate with outsized returns.
• Safety is ABBV’s strongest Component Grade rating, in which it ranks in the top 1% of stocks, indicating both a large degree of stock price stability relative to peers and a solid track record in terms of analyst predictions when it comes to earnings.
• However, AbbVie is no slouch when it comes to Financials and Artificial Intelligence either. In terms of the former, it ranks in the top 11% — in terms of the latter, in the top 10%. To distill those numbers into words, the company boasts quite a strong balance sheet, and the findings of a neural network trained on more than two decades of market data suggest ABBV shares are likely to outperform going forward. (See all 7 Zen Component Grades here >)

What to Do Next?

• 200 Stocks to Sell Now >
• See All “A” Rated Stocks with +32.52% Average Annual Return >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.